Our Technology
Homogeneous, glyco-engineered conjugates for safer, more potent antibody therapeutics.
Our site-specific conjugation platform delivers ADCs with enhanced stability, more precise DAR control, and improved clinical predictability compared to traditional conjugation methods, enabling more effective and targeted treatments for patients.
How It Works
1.
Glycan Remodeling
Highly engineered glycosidases precisely modify Fc-region glycans, creating uniform conjugation sites.
2.
Payload Attachment
3.
Homogeneous ADCs
4.
Clinic-Ready Quality
- Our Edge
Benefits That Matter
Development Efficiency
- Fast, High-Yield Reaction
- Scalable Reagents
Product Performance
- Pinpoint Precision
- Plug-and-Play Payloads
Why Enzymatic Glycoengineering Outperforms Conventional Conjugation
Xcellon’s enzymatic glyco-engineering (EG) platform delivers tangible advantages that conventional chemical conjugation cannot match.
Faster development cycles, lower manufacturing risk, and highly consistent, clinic-ready ADCs.
Accelerate Your Pipeline with Stronger therapeutic windows and clearer regulatory paths.
Leverage Xcellon’s enzymatic glyco-engineering and end-to-end development services to put these advantages to work for your program.
Partner
With Us
Partner With Us
Xcellon Biologics is backed by successful biotech entrepreneurs and professionals from top pharmaceutical and CDMO companies including Lonza, Abzena, Amgen, MedImmune, AstraZeneca, BioNTech, Seattle Genetics, and Immunomedics.
We collaborate with leading innovators and global partners to accelerate biopharmaceutical breakthroughs while maintaining the highest quality and regulatory standards.
